Eutilex said it has entered into a partnership with OBio Technology, a Chinese-based pharmaceutical company, to collaborate in clinical trials and commercialization of cell therapy pipelines in China.

Under the accord, Eutilex will start clinical trials and commercialize EBViNT, its killer T-cell therapy, and Chimeric Antigen Receptor T (CAR-T) therapy in China.

OBiO Technology will establish a good manufacturing practice (GMP) facility, contact contract research organization (CRO), and start the commercialization process to help Eutilex research and manufacture viral vectors, tumor viruses, and CAR-T in China.

"In consultation with OBio, which has sufficient experience in the clinical field and commercialization in China, we will cooperate in various forms so that we can quickly carry out clinical trials of Eutilex's cell therapy in China," Eutilex CEO Choi Soo-young said.

ObiO Technology CEO Guodong Jia also said, "Starting with this partnership, OBiO Technology will collaborate with Eutilex in many ways so that the company, which has excellent immunotherapy technology, can conduct successful business in China."